Ubs Group Ag Solid Biosciences Inc. Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$0.74 - $1.79 $28,865 - $69,824
-39,008 Reduced 93.98%
2,500 $3,000
Q4 2021

Feb 14, 2022
BUY
$1.69 - $2.46 $59,831 - $87,091
35,403 Added 579.9%
41,508 $72,000
Q3 2021

Nov 15, 2021
BUY
$2.38 - $3.77 $1,963 - $3,110
825 Added 15.63%
6,105 $15,000
Q2 2021

Aug 13, 2021
SELL
$3.49 - $5.51 $22,960 - $36,250
-6,579 Reduced 55.48%
5,280 $19,000
Q1 2021

May 12, 2021
SELL
$5.37 - $10.72 $21,807 - $43,533
-4,061 Reduced 25.51%
11,859 $66,000
Q4 2020

Feb 11, 2021
BUY
$3.08 - $7.79 $40,800 - $103,194
13,247 Added 495.59%
15,920 $121,000
Q3 2020

Nov 12, 2020
SELL
$2.02 - $3.08 $22,658 - $34,548
-11,217 Reduced 80.76%
2,673 $5,000
Q2 2020

Jul 31, 2020
SELL
$2.1 - $3.42 $95,386 - $155,343
-45,422 Reduced 76.58%
13,890 $40,000
Q1 2020

May 01, 2020
SELL
$2.31 - $4.43 $37,886 - $72,656
-16,401 Reduced 21.66%
59,312 $141,000
Q4 2019

Feb 14, 2020
SELL
$2.82 - $12.9 $15,966 - $73,039
-5,662 Reduced 6.96%
75,713 $337,000
Q3 2019

Nov 14, 2019
BUY
$4.33 - $11.64 $178,434 - $479,672
41,209 Added 102.6%
81,375 $842,000
Q2 2019

Aug 14, 2019
SELL
$4.6 - $10.13 $18,680 - $41,137
-4,061 Reduced 9.18%
40,166 $231,000
Q1 2019

May 14, 2019
SELL
$7.19 - $32.37 $527,264 - $2.37 Million
-73,333 Reduced 62.38%
44,227 $407,000
Q4 2018

Feb 14, 2019
BUY
$21.32 - $46.34 $1.48 Million - $3.23 Million
69,639 Added 145.32%
117,560 $3.15 Million
Q3 2018

Nov 14, 2018
BUY
$36.35 - $51.7 $273,969 - $389,662
7,537 Added 18.66%
47,921 $2.26 Million
Q2 2018

Aug 14, 2018
BUY
$7.33 - $43.15 $216,924 - $1.28 Million
29,594 Added 274.27%
40,384 $1.44 Million
Q1 2018

May 15, 2018
BUY
$7.19 - $33.17 $77,580 - $357,904
10,790 New
10,790 $81,000

Others Institutions Holding SLDB

# of Institutions
2
Shares Held
97
Call Options Held
0
Put Options Held
0
View Full List

About Solid Biosciences Inc.

SLDB Quotes by TradingView
  • Ticker SLDB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 7,533,080
  • Market Cap $30.6M
  • Description
  • Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...
More about SLDB
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email